The Food and Drug Administration (FDA) has issued a positive feedback on Hemerion’s clinical strategy following a Type C Meeting held in November 2025. The U.S. health authority confirmed the relevance of Hemerion’s proposed clinical and regulatory strategy for the Pentalafen® / Heliance® technology in the treatment of newly diagnosed glioblastoma patients in the United …
A newly published case report in the renowned Journal of Neuro-Oncology Discovery provides compelling clinical evidence of the feasibility, safety and workflow integration of the Pentalafen®/Heliance® combination therapy in treating glioblastoma. This case, drawn from the Hemerion-sponsored Phase 1/2 clinical trial at the University of Pittsburgh Medical Center, highlights the potential of Hemerion’s technology to …
Le Moci, the leading media outlet serving international trade professionals in France, awarded Hemerion the nationale LeadExport Trophy in the Innovation category in recognition of its international activities. This award recognises Hemerion’s efforts to accelerate the development of innovative cancer therapies on the global stage. This distinction recognizes the international expansion strategy pursued by Hemerion, …
The program supports investigator-sponsored clinical studies (ISS) or investigator-initiated trials (IIT). Our goal: to offer researchers and clinicians the opportunity to explore new indications, expand the use of Pentalafen®/Heliance® combination therapy, and push the boundaries of photodynamic therapy in cancer treatment. The ISS program is open to European and American surgeons and oncologists and allows …
To mark its fifth anniversary, Hemerion organized an exceptional Scientific Board Meeting at the Maison de la Chimie in Paris, open to investors and major players in the MedTech and Pharma/Biotech industries. The aim of this event was to unveil the latest clinical advances in glioblastoma and explore the potential of the Pentalafen/Heliance combination therapy …
Following the launch of its latest clinical study in the US, Hemerion has obtained authorization from the ANSM (French National Agency for Medicines and Health Products Safety) to open a new trial center at Lille University Hospital in July 2025.This opening confirms Hemerion’s ability to work effectively with health authorities on both sides of the …
Dr. Everardo Saad joins Hemerion as Medical Director. The appointment of this expert in oncology clinical trials marks Hemerion’s entry into a new phase of clinical investigation, with the upcoming launch of a pivotal study dedicated to its Pentalafen® / Heliance® technology in the treatment of glioblastoma and the expansion of its pipeline to other …
Hemerion participated for the first time this year in the Annual Meeting of the Congress of Neurosurgeons, the world’s largest event dedicated to neurosurgery, held in Los Angeles. Its combined Pentalafen®/Heliance® therapy attracted the attention of practitioners from around the world, as well as leading names in medtech. The Hemerion team presented its Heliance®/Pentalafen® combination …
In response to the acceleration of its preclinical and clinical research programs, Hemerion appointed Mélanie Rose to lead the innovation and expansion of its therapeutic solution pipeline based on Pentalafen® Heliance® technology. Already in an advanced clinical stage for the treatment of glioblastoma, this therapeutic platform could quickly find new applications in oncology as a complement …
Hemerion continues its international expansion with its first participation in the world’s largest neurosurgery event. This is an opportunity to preview its upcoming pivotal multicenter clinical trial to the most influential specialists in global neurosurgery. The Annual Meeting of the Congress of Neurosurgeons will be held at the Los Angeles Convention Center from October 10 …